Amalgamated Bank Arvinas, Inc. Transaction History

Amalgamated Bank

$12.1 Billion
Q3 2024

A detailed history of Amalgamated Bank transactions in Arvinas, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,223 shares of ARVN stock, worth $42,414. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,223

Previous 2,223 -0.0%

Holding current value

$42,414

Previous $59,000 6.78%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$24.46 - $40.4 $12,425 - $20,523	508 Added 29.62%	2,223 $59,000
Q1 2024 Apr 23, 2024	SELL	$36.38 - $52.31 $187,247 - $269,239	-5,147 Reduced 75.01%	1,715 $71,000
Q4 2023 Feb 06, 2024	SELL	$14.19 - $42.33 $7,194 - $21,461	-507 Reduced 6.88%	6,862 $282,000
Q2 2023 Aug 11, 2023	BUY	$21.73 - $31.43 $12,190 - $17,632	561 Added 8.24%	7,369 $182,000
Q1 2023 May 02, 2023	SELL	$26.15 - $37.26 $31,249 - $44,525	-1,195 Reduced 14.93%	6,808 $186,000
Q4 2022 Feb 10, 2023	BUY	$32.47 - $57.24 $5,649 - $9,959	174 Added 2.22%	8,003 $274,000
Q3 2022 Nov 09, 2022	BUY	$41.87 - $57.99 $5,191 - $7,190	124 Added 1.61%	7,829 $348,000
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $252 - $519	-7 Reduced 0.09%	7,705 $324,000
Q1 2022 Jun 30, 2022	SELL	$60.27 - $81.57 $33,992 - $46,005	-564 Reduced 6.81%	7,712 $519,000
Q4 2021 Feb 15, 2022	BUY	$65.85 - $96.21 $33,715 - $49,259	512 Added 6.59%	8,276 $680,000
Q3 2021 Oct 29, 2021	SELL	$73.2 - $107.87 $34,916 - $51,453	-477 Reduced 5.79%	7,764 $638,000
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $186,911 - $260,531	3,092 Added 60.05%	8,241 $635,000
Q1 2021 May 13, 2021	SELL	$58.19 - $91.37 $12,278 - $19,279	-211 Reduced 3.94%	5,149 $340,000
Q4 2020 Feb 12, 2021	BUY	$20.19 - $84.93 $108,218 - $455,224	5,360 New	5,360 $455,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.

Account

Amalgamated Bank Arvinas, Inc. Transaction History